Skip to content

Structures and Small Molecule Inhibitors in Cellular and Animal Models

My WordPress Blog

Menu
  • Sample Page
Menu

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm

Posted on June 20, 2022 by president2010

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. 1 g/ml), and V4 (IC50, 5 g/ml) epitopes. In comparison, SIVmac251 and SIVmac239 were highly resistant to neutralization by these same antibodies. Differences in neutralization sensitivity between SIVsmE660 and SIVmac251/239 were not dependent on the cell type in which virus was produced or tested. These findings indicate that in comparison to SIVmac251/239 and primary HIV-1 viruses, SIVsmE660 generally exhibits substantially less masking of antigenically conserved Env epitopes. Interestingly, we identified a minor population of viruses (10%) in both the SIVsmE660 isolate and T/F viruses arising from it that were substantially more resistant ( 1,000-fold) to antibody neutralization and another fraction (20%) that was intermediate in neutralization resistance. These findings may explain the variable natural history and variable protection afforded by heterologous Env-based vaccines in rhesus macaques challenged by high-dose versus low-dose SIVsmE660 inoculation regimens. INTRODUCTION Similarities between simian immunodeficiency virus (SIV) contamination of rhesus macaques and human immunodeficiency virus type 1 (HIV-1) contamination of humans were first recognized in the 1980s, when captive Asian-origin macaques were found to be infected with an immunodeficiency-causing retrovirus originating with African-origin sooty mangabeys (1C6). Whereas SIVsmm viruses cause a nonpathogenic contamination in their natural hosts (7), they produce a pathogenic contamination in macaques, with virologic and clinical outcomes that parallel those of HIV-1 contamination in humans. Like HIV-1, SIVsmm and SIVmac infect CD4+ T cells, utilize CCR5 as a coreceptor, establish high peak and setpoint Halofuginone viremia, and cause generalized immune activation and a profound acute Halofuginone and sustained loss of intestinal CD4+ T cells (3, 8, 9). As in HIV-1 contamination, these events lead to progressive immune deficiency, opportunistic infections, AIDS-defining neoplasms, and death in the majority of infected animals (10). Given these parallels with HIV contamination, the SIV-nonhuman primate (NHP) model has been utilized as an important component of HIV vaccine development efforts. There are many iterations of this NHP Halofuginone model, with options in animal species, challenge viruses, inoculation routes, dosing strategies, and intrinsic host genetic restriction factors. Though there is no single standardized SIV-NHP contamination model, much of the recent work in antibody- and cell-based vaccine design and assessment has been conducted with Indian-origin rhesus macaques challenged with SIVsmm and SIVmac viruses. Two of the most commonly used challenge viruses in the macaque model are the isolates SIVsmE660 and SIVmac251, along with the latter’s derivative clone SIVmac239. SIVsmE660 was originally isolated from a rhesus macaque (Rh660) with a terminal AIDS-defining illness after it had been infected with virus previously passaged through three rhesus macaques. The Rh660 spleen homogenate was then cocultured with human CEMx174 cells and passaged through pigtail macaque peripheral blood mononuclear cells (PBMCs) to obtain the virus challenge stock (9, 11). SIVmac251 was also isolated terminally from SIV-infected macaque spleen cells after the macaque Halofuginone had been infected with virus cocultured with human PBMCs and serially passaged through rhesus PBMC cultures (12). Based on uncorrected mean character differences, the SIVmac251 and SIVsmE660 virus swarms are each approximately 77% Agt identical in amino acid sequence to HIV-2, which originated from a cross-species transmission of SIVsmm from sooty mangabeys to humans, but only 52 to 57% identical to HIV-1 (9, 13C16). Despite these differences in primary amino acid sequence, SIVsmE660, SIVmac251, HIV-2, and HIV-1 are all highly related from an envelope (Env) structure-function perspective (15, 16). SIVsmE660 and SIVmac251 each exhibit modest within-isolate genetic heterogeneity, with 1.8% and 2.6% maximum diversity for SIVsmE660 and SIVmac251, respectively. The genetic distance between the SIVsmE660 and SIVmac251 lineages in is substantially greater, 14.6% in nucleotide sequence and a 13.5% difference in amino acid sequence, based on uncorrected mean character differences. This interlineage diversity has made these virus strains attractive candidates for heterologous Halofuginone challenge studies of candidate HIV vaccines. Uncloned challenge stocks of SIVsmE660 and SIVmac251 have been used to test various vaccine.

Recent Posts

  • First, LSD1 is unable to demethylate histone tails while the SNAG domain name of GFI1, which mimics the structure of the N-terminal tail of histone H3 (Baron et?al
  • 4 Combined treatment with chidamide and MI-3 disrupts DNA damage response
  • A lot of the substances were identified predicated on books data and/or our previously published functions
  • Amount 10F demonstrates the colocalization of viral capsids with actin filaments, and Light fixture-1, a marker for the later endosome/lysosome (Video S15)
  • Our study shows a negative correlation between the level of HGA areas and cellulose degradability, indicating that HGA level is a trait that may be exploited for any wide-scale selection and breeding of vegetation for biofuel production

Recent Comments

  1. A WordPress Commenter on Hello world!

Archives

  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021

Categories

  • Acetylcholine ??7 Nicotinic Receptors
  • Acetylcholine Nicotinic Receptors
  • Acyltransferases
  • Alpha1 Adrenergic Receptors
  • Angiotensin Receptors, Non-Selective
  • APJ Receptor
  • Calcium Channels
  • Carrier Protein
  • cMET
  • COX
  • DAT
  • Decarboxylases
  • Dipeptidyl Peptidase IV
  • DP Receptors
  • FFA1 Receptors
  • GlyR
  • H1 Receptors
  • HDACs
  • Hsp90
  • IGF Receptors
  • LXR-like Receptors
  • Miscellaneous Glutamate
  • Neurokinin Receptors
  • Nicotinic Acid Receptors
  • Nitric Oxide, Other
  • NO Synthase, Non-Selective
  • Non-selective Adenosine
  • Nucleoside Transporters
  • Opioid, ??-
  • Oxidative Phosphorylation
  • p70 S6K
  • PI 3-Kinase
  • Platelet-Activating Factor (PAF) Receptors
  • Potassium (KV) Channels
  • Potassium Channels, Non-selective
  • Prostanoid Receptors
  • Protein Ser/Thr Phosphatases
  • PTP
  • Retinoid X Receptors
  • Serotonin (5-ht1E) Receptors
  • Shp2
  • Sigma1 Receptors
  • Signal Transducers and Activators of Transcription
  • Sirtuin
  • Syk Kinase
  • T-Type Calcium Channels
  • Ubiquitin E3 Ligases
  • Ubiquitin/Proteasome System
  • Uncategorized
  • Urotensin-II Receptor
  • Vesicular Monoamine Transporters
© 2023 Structures and Small Molecule Inhibitors in Cellular and Animal Models | Powered by Minimalist Blog WordPress Theme